在患有心血管疾病的老年患者中开发潜在不合适药物的预测模型
Chun-Ying Lee1,2, Yun-Shiuan Chuang1,2,3, Chew-Teng Kor4
1Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
这项研究开发了预测模型,以识别患有心血管疾病 (CVD) 的老年人潜在不合适药物 (PIM). 关键的临床因素,如胆固醇和HbA1c水平有助于评估PIM风险.
科学领域:
- 老年医学 老年医学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有心血管疾病 (CVD) 的老年人面临药物不良反应的风险增加.
- 导致这种情况的因素包括生理变化,并发症,多药性和潜在不适当的药物 (PIMs).
研究的目的:
- 开发一种预测模型,用于识别在被诊断患有心血管疾病的老年患者中使用PIM.
- 提高药物安全性和临床决策对于这个弱势群体.
主要方法:
- 利用了来自两个医院数据库 (CCHRD和KMUHRD) 的2012-2021年的数据.
- 包括65岁以上有心血管疾病诊断的患者.
- 使用培训和内部/外部验证集开发和验证预测模型.
主要成果:
- 分析了48,569名患者,确定了PIM使用与胆固醇,HbA1c,肌素,尿酸,糖尿病,高血压和脑血管事故等因素之间的显著关联.
- 开发的预测模型显示了适度的预测能力.
结论:
- 成功开发了预测模型,以了解PIM在老年心血管疾病患者中的使用.
- 这些模型可以帮助临床医生优化药物安全和管理.
更多相关视频
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
相关概念视频
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Analysis of Population Pharmacokinetic Data
Cardiovascular Drugs: Classification based on Therapeutic Indications
